Cardiology Question for the Week of May 22, 2017
When it is billed, does For LUMASON® (sulfur hexafluoride lipid-type A microsphere) for injectable suspension, for intravenous use or intravesical use need a separate diagnosis, or is it covered under the primary reason the echo was ordered? Previously (ICD- 9) we used 794.39 (abnormal result of other cardiovascular function study) to bill for any enhancer used during an echo. Should we still be doing this with the new ICD-10 code R94.39 (abnormal result of other cardiovascular function study)?